LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Buy” from Brokerages

LivaNova PLC (NASDAQ:LIVN) has been assigned a consensus rating of “Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $69.17.

A number of brokerages have weighed in on LIVN. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 25th. Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. Mizuho lowered their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Robert W. Baird increased their target price on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research note on Monday, November 25th.

Insider Activity

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of LivaNova

A number of large investors have recently made changes to their positions in the stock. Central Pacific Bank Trust Division boosted its holdings in LivaNova by 21.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after purchasing an additional 720 shares during the last quarter. Sanctuary Advisors LLC bought a new position in shares of LivaNova during the 3rd quarter valued at $219,000. Geode Capital Management LLC boosted its stake in shares of LivaNova by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock worth $70,676,000 after buying an additional 8,331 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of LivaNova in the third quarter worth $550,000. Finally, Point72 DIFC Ltd increased its position in LivaNova by 75,799.6% during the third quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock valued at $9,531,000 after acquiring an additional 181,161 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Stock Performance

Shares of LIVN stock opened at $47.27 on Friday. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The company’s fifty day moving average price is $50.28 and its 200-day moving average price is $50.61. The stock has a market cap of $2.57 billion, a PE ratio of 112.55 and a beta of 0.98. LivaNova has a 12 month low of $43.15 and a 12 month high of $64.47.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.